Le Lézard
Classified in: Health, Sports and recreation
Subject: PDT

InventHelp Inventor Develops Newly Formulated Mosquito Repellant (CPC-787)


PITTSBURGH, May 10, 2024 /PRNewswire/ -- "I wanted to create a new type of mosquito repellant that can be worn on any area of the body to deter bites and irritation," said an inventor, from Waterbury, Conn., "so I invented the BYE BYE. My design enables you to enjoy a backyard party, barbecue, camping or other outdoor activity without worrying about mosquito bites."

The patent-pending invention provides a specially formulated repellant for mosquitoes. In doing so, it would serve as a more effective alternative to conventional mosquito repellants. As a result, it helps prevent painful and irritating bites, and it offers added protection and peace of mind. The invention features an effective and lightweight design that is easy to apply and use so it is ideal for adults and children. Additionally, it is producible in design variations.

The original design was submitted to the Connecticut sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 22-CPC-787, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at http://www.InventHelp.com.

SOURCE InventHelp


These press releases may also interest you

at 14:20
Gastroesophageal Reflux Disease (GERD) Market size is set to grow by USD 879.8 million from 2024-2028, Rising geriatric population to boost the market growth, Technavio
The global gastroesophageal reflux disease (GERD) market  size is estimated to grow by USD 879.8 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  3.2%  during the forecast period.  Rising geriatric...

at 12:48
Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransContm PTH in Canada
Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement with Ascendis Pharma A/S ("Ascendis"), a global biopharmaceutical company headquartered in Copenhagen, Denmark. Under the terms of...

at 12:36
IMPERIAL TOBACCO CANADA ADVOCATES FOR A NEW FEDERAL FRAMEWORK THAT TREATS ALL NICOTINE REPLACEMENT THERAPIES (NRTs) EQUALLY
Imperial Tobacco Canada Limited ("ITCAN") has officially submitted its feedback to Health Canada regarding the proposed Ministerial Order on nicotine replacement therapy products (NRTs). ITCAN strongly believes that NRTs, especially innovative...

at 12:20
Global Regenerative Medicine Partnering Deals Analysis Report and Directory 2016-2024: 1771 Collaboration, Development, Research and Licensing Deals by Company A-Z, Deal Type and Therapy Area - ResearchAndMarkets.com
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...

at 12:10
Diagnostic Imaging Partnering Analysis Report and Directory 2016-2024: 628 Collaboration, Development, Research and Licensing Deals by Company A-Z, Deal Type and Therapy Area - ResearchAndMarkets.com
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...

at 12:05
KFSH&RC Achieves Remarkable 98% Survival Rate in 400 Robotic Cardiac Surgeries
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of...

More news about Health...


News published on and distributed by: